Expertise in
51
conditions

Dr. Mitchell B. Alden

Oncology
599 West State Street, Suite 312, 
Doylestown, PA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Referral may be required
Before you request
Expertise in
51
conditions
599 West State Street, Suite 312, 
Doylestown, PA 

Overview

Mitchell Alden is an Oncologist practicing medicine in Doylestown, Pennsylvania.

Dr. Alden is highly rated in 51 conditions, according to our data. His clinical expertise encompasses Familial Colorectal Cancer, Colorectal Cancer, Lung Cancer, and Pleuropulmonary Blastoma.

He is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 11 clinical trials. Dr. Alden is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in PA

Fellowships

Fox Chase Cancer Center

Hospital Affiliations

Hospital Of Univ Of Pennsylvania
St Luke's Hospital - Grand View Campus
Doylestown Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Avalon Health Care
  • MEDICARE PDP
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

Alliance Cancer Specialists Doylestown
599 West State Street, Suite 312, Doylestown, PA 18901
Other Locations
Alliance Cancer Specialists Sellersville
915 Lawn Avenue, Sellersville, PA 18960

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

International Registry for Men With Advanced Prostate Cancer (IRONMAN)
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
Enrollment Status: Recruiting
Publish Date: May 22, 2026
Intervention Type: Other
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Drug
Study Drugs: Endoxifen Hydrochloride, Tamoxifen Citrate
Study Phase: Phase 2
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Entinostat, Exemestane, Goserelin, Goserelin Acetate
Study Phase: Phase 3
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Completed
Publish Date: December 31, 2025
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
View 9 Less Clinical Trials

1 Total Publications

SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer.
SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 23, 2024
Similar Doctors
Expertise in
17
conditions
Dr. Hossein Borghaei
Oncology | Radiology | Hematology
Expertise in
17
conditions
Dr. Hossein Borghaei
Oncology | Radiology | Hematology
Referral may be required

Fox Chase Cancer Center

333 Cottman Ave, 
Philadelphia, PA 
 (16.5 miles away)
888-369-2427
Languages Spoken:
English, Spanish
See accepted insurances
Offers Telehealth

Hossein Borghaei is an Oncologist and a Radiologist practicing medicine in Philadelphia, Pennsylvania. Dr. Borghaei is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer. Dr. Borghaei is board certified in American Board Of Internal Medicine - Medical Oncology.

Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required

University Of Pennsylvania

3400 Civic Center Blvd, 
Philadelphia, PA 
 (24.9 miles away)
215-615-5858
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jakub Svoboda is an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Svoboda is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Classical Hodgkin Lymphoma, B-Cell Lymphoma, and Bone Marrow Aspiration.

Expertise in
14
conditions
Expertise in
14
conditions
Referral may be required
Before you request

Penn Mesothelioma And Pleural Program

51 N. 39th Street, Pavilion For Advanced Care, First Floor, 
Philadelphia, PA 
 (24.2 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Corey Langer is an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Langer is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Mesothelioma, Small Cell Lung Cancer (SCLC), and Tissue Biopsy. Dr. Langer is board certified in Hematology, 1986, Medical Oncology, 1987, and Internal Medicine, 1984. Dr. Langer is currently accepting new patients.

Frequently Asked Questions about Dr. Mitchell B. Alden

How do I make an appointment with Dr. Mitchell B. Alden?

You can book an appointment with Dr. Mitchell B. Alden by calling their office at 800-789-7366. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mitchell B. Alden a top-rated expert for Familial Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mitchell B. Alden is classified as an Distinguished expert for Familial Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mitchell B. Alden specialize in?

While Dr. Mitchell B. Alden is a Oncology, they have specific expertise in Familial Colorectal Cancer, Colorectal Cancer, and Lung Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Mitchell B. Alden participate in research or clinical trials?

Yes. Dr. Mitchell B. Alden has published 1 articles and abstracts on conditions like Familial Colorectal Cancer. You can view a list of Dr. Mitchell B. Alden's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mitchell B. Alden accept my insurance?

Dr. Mitchell B. Alden accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 800-789-7366 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Alden's expertise for a condition
ConditionClose
    View All 45 Advanced Conditions
    View All 86 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile